Business
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting
NEW HAVEN, Conn., March 18, 2026--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that three abstracts will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting being held in Denver, Colorado on March 27 – 31, 2026.
About this update from Veradermics, Incorporated
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1500,"height":450,"url":"https://media.zenfs.com/en/business-wire.com/3c98f355ec2084467e1919a8d49ebd87"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2qa2wWwG3NFNXJ7veiAyBw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI4ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3c98f355ec2084467e1919a8d49ebd87","width":960,"height":288},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/8lbzCbN4a5OmCOfr_up0pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/3c98f355ec2084467e1919a8d49ebd87","width":1200,"height":360}},"lazy":false},{"type":"text","content":"NEW HAVEN, Conn., March 18, 2026--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that three abstracts will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting being held in Denver, Colorado on March 27 – 31, 2026.","length":434,"tagName":"p"},{"type":"text","content":"The data to be presented include a blinded, retrospective investigator global assessment conducted by six independent dermatologists regarding the comparative perceived efficacy of VDPHL01 versus existing minoxidil formulations and the clinical potential of VDPHL01. In addition, two presentations will characterize social listening research on patient perceptions and experiences, describing general frustration with current pattern hair loss treatments.","length":455,"tagName":"p"},{"type":"text","content":"Details of the Veradermics presentations are as follows:Title: Faster Onset and Superior Efficacy of an Investigational Extended-Release Oral Minoxidil Tablet (VDPHL01) Versus Topical and Immediate-Release Oral Minoxidil for Androgenetic Alopecia: Results from a Blinded Retrospective Investigator Global AssessmentAbstract: 76221 (e-poster)","length":343,"tagName":"p"},{"type":"text","content":"Title: Social Listening Analysis of 143,000 Online Conversations on Hair Loss Treatments: Side Effects, Satisfaction, and DiscontinuationAbstract: 75995Date/Time: Mar 27, 2026, 11:25-11:30am MTLocation: Colorado Convention Cente...